Neutralizing antibody response variation against dengue 3 strains

Journal of Medical Virology

Volumn 80, Issue 10, 2008, Pages 1783-1789

  Alvarez, Mayling ^a   Pavon Oro, Alequis ^a   Rodriguez Roche, Rosmari ^a   Bernardo, Lídice ^a   Morier, Luís ^a   Sanchez, Lizet ^a   Alvarez, Angel M ^a   Guzmán, Maria G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Dengue fever and dengue hemorrhagic fever; Dengue genotype; Havana epidemics; Human sera panel; Late convalescent sera; Plaque reduction neutralization technique

Indexed keywords

NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONVALESCENCE; DENGUE; DENGUE VIRUS; DENGUE VIRUS 3; EPIDEMIC; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONHUMAN; VIRUS CULTURE; VIRUS DETECTION; VIRUS STRAIN;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CONVALESCENCE; CUBA; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS; PLAQUE ASSAY;

EID: 50849091313     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21234     Document Type: Article

References (34)

1. Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman G. 2005. Improved dengue virus plaque formation on BHK21 and LLCMK2 Cells: Evaluation of some factors. Dengue Bull 29:49-57.
2. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, Castro O, Kouri G, Halstead SB, Guzman MG. 2006. Dengue hemorrhagic Fever caused by sequential dengue1-3virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg 75:1113-1117.
3. Cologna R, Rico-Hesse R. 2003. American genotype structures decrease dengue virus output from human monocytes and dendritic cells J Virol 77:3929-3938.
4. Fernandez RJ, Vazquez S. 1990. Serological diagnosis of dengue by an ELISA inhibition method (EIM). Mem Inst Oswaldo Cruz 85:347-351.
5. Gubler DJ. 1997. The emergence of dengue/dengue haemorrhagic fever as a global public health problem. In: Saluzzo JF, Dodet B, editors. Factors in the emergence of arbovirus diseases. Paris: Elsevier. pp 83-92.
6. Guzman MG, Kouri G. 2002. Dengue: An update. Lancet Infect Dis 2:33-42.
7. Guzman MG, Alvarez M, Rodriguez R, Rosario D, Vazquez S, Valds L, Cabrera MV, Kouri G. 1999. Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis 3:130-135.
8. Guzman MG, Kouri G, Halstead SB. 2000. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? Lancet 355:1902-1903.
9. Halstead SB. 1988. Pathogenesis of dengue: Challenges to molecular biology. Science 239:476-481.
10. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467.
11. Halstead SB, O'Rourke EJ. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146:201-217.
12. Halstead SB, Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42:311-328.
13. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. 2005. Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003,Vienna, Austria. Vaccine 23:849-856.
14. Holmes EC, Burch SS. 2000. The causes and consequences of genetic variation in dengue virus. Trends Microbiol 8:74-77.
15. Keelapang P, Tariyo P, Butphet S, Hachaibhum J, Puttikhunt C, Kasinrek W, Malasit P, Sittisombut N. 2004. Role of anti-preM antibodies in neutralisation of dengue virus. Meeting on Flavivirus Vaccines, WHO Steering Committee, Thailand.
16. Kouri GP, Guzman MG, Bravo JR. 1987. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans R Soc Trop Med Hyg 81:821-823.
17. Kurane I. 2003. Dengue virus. Nippon Rinsho 61:486-490.
18. Lanciotti RS, Lewis JG, Gubler DJ, Trent DW. 1994. Molecular evolution and epidemiology of dengue-3 viruses. J Gen Virol 75:65-75.
19. Lanciotti RS, Gubler DJ, Trent DW. 1997. Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol 78:2279-2284.
20. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, Ramos C, Rico Hesse R. 1999. Dengue virus structural differences that correlate with pathogenesis. J Virol 73:4738-4747.
21. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. 2003. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9:800-809.
22. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: Comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22:250-254.
23. Morens DM, Venkateshan CN, Halstead SB. 1987. Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J Gen Virol 68:91-98.
24. Pelaez O, Guzman MG, Kouri G, Perez R, San Martin JL, Vazquez S, Rosario D, Mora R, Quintana I, Bisset J, Cancio R, Masa AM, Castro O, Gonzalez D, Avila LC, Rodriguez R, Alvarez M, Pelegrino JL, Bernardo L, Prado I. 2004. Dengue 3 epidemic, Havana,2001. Emerg Infect Dis 10:719-722.
25. Polizel JR, Bueno D, Visentainer JE, Sell AM, Borelli SD, Tsuneto LT, Dalalio MM, Coimbra MT, Moliterno RA. 2004. Association of human leukocyte antigen DQ1 and dengue fever in a white Southern Brazilian population. Mem Inst Oswaldo Cruz 99:559-562.
26. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, Wright PJ. 2001. Replication of dengue virus type 2 in human monocyte-derived macrophages: Comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 65:427-434.
27. Rico Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, Boshell J, de Mesa MT, Nogueira RM, da Rosa AT. 1997. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230:244-251.
28. Rico-Hesse R. 1990. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174:479-493.
29. Rico-Hesse R. 2003. Microevolution and virulence of dengue viruses. Adv Virus Res 59:315-341.
30. Rodriguez-Roche R, Alvarez M, Holmes EC, Bernardo L, Kouri G, Gould EA, Halstead S, Guzman MG. 2005a. Dengue virus type 3, Cuba, 2000-2002. Emerg Infect Dis 11:773-774.
31. Rodriguez-Roche R, Alvarez Vera M, Gritsun T, Halstead S, Kouri G, Gould EA, Guzman M. 2005b. Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology 334:154-159.
32. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, Endy TP, Library DH, Nisalak A, Innis BL, Rothman AL, Ennis FA, Chandanayingyong D. 2002. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60:309-318.
33. Uzcategui NY, Comach G, Comacho D, Salcedo M, Cabello de Quintana M, Jimenez M, et al. 2003. Molecular epidemiology of dengue virus type 3 in Venezuela. J Gen Virol 84:1569-1575.
34. Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, Prado I, Chinea G, Rosario D, Guillen G, Guzman MG. 2006. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121:65-73.